Marinomed Biotech AG (FRA:93Z)

Market Cap	9.00M -74.5%
Revenue (ttm)	7.96M +66.1%
Net Income	18.02M
EPS	9.79
Shares Out	n/a
PE Ratio	0.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	4.240
Previous Close	4.080
Day's Range	4.240 - 4.240
52-Week Range	3.000 - 20.600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 16, 2026

About Marinomed Biotech AG

Marinomed Biotech AG operates as a biopharmaceutical company in Austria, other European countries, and internationally. Its lead products include Budesolv for the treatment of allergic rhinitis in late-stage clinical development; and Tacrosolv for the treatment of inflammatory eye diseases in Phase II clinical studies. The company also develops Satiasolv for pain immune reactions in the preclinical development phase. In addition, it provides Solv4U for formulation development and biopharmaceutical testing services. The company was formerly know...

• Industry: Pharmaceutical Preparations
• Founded: 2006
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 93Z

Financial Performance

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error